187 related articles for article (PubMed ID: 16098291)
1. Initial staging of lymphoma with octreotide and other receptor imaging agents.
Ferone D; Semino C; Boschetti M; Cascini GL; Minuto F; Lastoria S
Semin Nucl Med; 2005 Jul; 35(3):176-85. PubMed ID: 16098291
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin receptors in malignant lymphomas: targets for radiotherapy?
Dalm VA; Hofland LJ; Mooy CM; Waaijers MA; van Koetsveld PM; Langerak AW; Staal FT; van der Lely AJ; Lamberts SW; van Hagen MP
J Nucl Med; 2004 Jan; 45(1):8-16. PubMed ID: 14734660
[TBL] [Abstract][Full Text] [Related]
3. The role of octreotide scintigraphy in rheumatoid arthritis and sarcoidosis.
Dalm VA; van Hagen PM; Krenning EP
Q J Nucl Med; 2003 Dec; 47(4):270-8. PubMed ID: 14973419
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin-receptor scintigraphy for staging and follow-up of patients with extraintestinal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT)-type.
Raderer M; Traub T; Formanek M; Virgolini I; Osterreicher C; Fiebiger W; Penz M; Jäger U; Pont J; Chott A; Kurtaran A
Br J Cancer; 2001 Nov; 85(10):1462-6. PubMed ID: 11720429
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and staging of children's lymphoma using the technetium-labelled somatostatin analogue, 99mTc-depreotide.
Cholewinski W; Kowalczyk JR; Stefaniak B; Stefaniak J; Poniatowicz-Frasunek E; Tarkowska A
Eur J Nucl Med Mol Imaging; 2004 Jun; 31(6):820-4. PubMed ID: 14762697
[TBL] [Abstract][Full Text] [Related]
6. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
Hofland LJ; Lamberts SW; van Hagen PM; Reubi JC; Schaeffer J; Waaijers M; van Koetsveld PM; Srinivasan A; Krenning EP; Breeman WA
J Nucl Med; 2003 Aug; 44(8):1315-21. PubMed ID: 12902423
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine aspects of immunolymphoproliferative diseases.
Ferone D; Hofland LJ; Colao A; Lamberts SW; van Hagen PM
Ann Oncol; 2001; 12 Suppl 2():S125-30. PubMed ID: 11762338
[TBL] [Abstract][Full Text] [Related]
8. [Somatostatin receptor-based imaging and therapy of digestive endocrine tumors].
Illouz F; Sadoul JL; Rohmer V
Ann Endocrinol (Paris); 2010 Sep; 71 Suppl 1():S3-12. PubMed ID: 21237328
[TBL] [Abstract][Full Text] [Related]
9. Initial staging of lymphoma with positron emission tomography and computed tomography.
Hicks RJ; Mac Manus MP; Seymour JF
Semin Nucl Med; 2005 Jul; 35(3):165-75. PubMed ID: 16098290
[TBL] [Abstract][Full Text] [Related]
10. The present and future role of (111)In pentetreotide in the PET era.
Rambaldi PF; Cuccurullo V; Briganti V; Mansi L
Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):225-35. PubMed ID: 16172568
[TBL] [Abstract][Full Text] [Related]
11. Imaging of neuroendocrine tumors.
Rufini V; Calcagni ML; Baum RP
Semin Nucl Med; 2006 Jul; 36(3):228-47. PubMed ID: 16762613
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas.
Reubi JC; Waser B; van Hagen M; Lamberts SW; Krenning EP; Gebbers JO; Laissue JA
Int J Cancer; 1992 Apr; 50(6):895-900. PubMed ID: 1348240
[TBL] [Abstract][Full Text] [Related]
14. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
15. Peptide receptor imaging and therapy.
Kwekkeboom D; Krenning EP; de Jong M
J Nucl Med; 2000 Oct; 41(10):1704-13. PubMed ID: 11038002
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin receptor scintigraphy in the initial staging of low-grade non-Hodgkin's lymphomas.
Lugtenburg PJ; Löwenberg B; Valkema R; Oei HY; Lamberts SW; Eijkemans MJ; van Putten WL; Krenning EP
J Nucl Med; 2001 Feb; 42(2):222-9. PubMed ID: 11216520
[TBL] [Abstract][Full Text] [Related]
17. Radiolabeled octreotide for the demonstration of somatostatin receptors in malignant lymphoma and lymphadenopathy.
Lipp RW; Silly H; Ranner G; Dobnig H; Passath A; Leb G; Krejs GJ
J Nucl Med; 1995 Jan; 36(1):13-8. PubMed ID: 7799065
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic applications of radiolabeled peptides in nuclear endocrinology.
Behr TM; Béhé M; Becker W
Q J Nucl Med; 1999 Sep; 43(3):268-80. PubMed ID: 10568142
[TBL] [Abstract][Full Text] [Related]
19. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
Boni G; Ferdeghini M; Bellina CR; Matteucci F; Castro Lopez E; Parenti G; Canapicchi R; Bianchi R
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
[TBL] [Abstract][Full Text] [Related]
20. Radiolabeled peptides in diagnosis and tumor imaging: clinical overview.
Warner RR; O'dorisio TM
Semin Nucl Med; 2002 Apr; 32(2):79-83. PubMed ID: 11965602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
